Wells Fargo’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.4M | Sell |
61,405
-28,256
| -32% | -$4.88M | ﹤0.01% | 2004 |
|
|
2025
Q4 | $16.4M | Buy |
89,661
+34,388
| +62% | +$4.8M | ﹤0.01% | 1646 |
|
|
2025
Q3 | $6.71M | Sell |
55,273
-430
| -0.8% | -$48.4K | ﹤0.01% | 2330 |
|
|
2025
Q2 | $5.81M | Buy |
55,703
+14,088
| +34% | +$1.49M | ﹤0.01% | 2354 |
|
|
2025
Q1 | $4.85M | Buy |
41,615
+1,879
| +5% | +$214K | ﹤0.01% | 2434 |
|
|
2024
Q4 | $3.36M | Sell |
39,736
-221
| -0.6% | -$20.3K | ﹤0.01% | 2779 |
|
|
2024
Q3 | $3.59M | Sell |
39,957
-95,898
| -71% | -$8.37M | ﹤0.01% | 2612 |
|
|
2024
Q2 | $10.9M | Buy |
135,855
+108,813
| +402% | +$8.06M | ﹤0.01% | 1651 |
|
|
2024
Q1 | $2.16M | Buy |
27,042
+7,396
| +38% | +$621K | ﹤0.01% | 2915 |
|
|
2023
Q4 | $1.56M | Buy |
19,646
+724
| +4% | +$48.4K | ﹤0.01% | 3109 |
|
|
2023
Q3 | $1.32M | Sell |
18,922
-9,468
| -33% | -$708K | ﹤0.01% | 3122 |
|
|
2023
Q2 | $2.04M | Sell |
28,390
-37,878
| -57% | -$2.79M | ﹤0.01% | 2900 |
|
|
2023
Q1 | $4.09M | Sell |
66,268
-10,698
| -14% | -$703K | ﹤0.01% | 2282 |
|
|
2022
Q4 | $5.94M | Buy |
76,966
+3,144
| +4% | +$188K | ﹤0.01% | 1949 |
|
|
2022
Q3 | $3.29M | Buy |
73,822
+64,144
| +663% | +$3.21M | ﹤0.01% | 2313 |
|
|
2022
Q2 | $370K | Buy |
9,678
+6
| +0.1% | +$190 | ﹤0.01% | 3923 |
|
|
2022
Q1 | $400K | Sell |
9,672
-5,476
| -36% | -$170K | ﹤0.01% | 4568 |
|
|
2021
Q4 | $572K | Buy |
15,148
+12,678
| +513% | +$466K | ﹤0.01% | 4553 |
|
|
2021
Q3 | $81K | Sell |
2,470
-701
| -22% | -$27.3K | ﹤0.01% | 5464 |
|
|
2021
Q2 | $214K | Sell |
3,171
-4,267
| -57% | -$256K | ﹤0.01% | 5001 |
|
|
2021
Q1 | $421K | Sell |
7,438
-16,411
| -69% | -$1.15M | ﹤0.01% | 4778 |
|
|
2020
Q4 | $1.94M | Buy |
23,849
+9,767
| +69% | +$730K | ﹤0.01% | 3519 |
|
|
2020
Q3 | $1M | Sell |
14,082
-9,619
| -41% | -$750K | ﹤0.01% | 3862 |
|
|
2020
Q2 | $1.95M | Sell |
23,701
-23,321
| -50% | -$1.79M | ﹤0.01% | 3278 |
|
|
2020
Q1 | $2.77M | Buy |
47,022
+2,341
| +5% | +$191K | ﹤0.01% | 2734 |
|
|
2019
Q4 | $4.62M | Sell |
44,681
-9,226
| -17% | -$373K | ﹤0.01% | 2636 |
|
|
2019
Q3 | $1.09M | Buy |
53,907
+6,357
| +13% | +$163K | ﹤0.01% | 3775 |
|
|
2019
Q2 | $1.23M | Buy |
47,550
+40,525
| +577% | +$812K | ﹤0.01% | 3730 |
|
|
2019
Q1 | $100K | Sell |
7,025
-2,175
| -24% | -$20.2K | ﹤0.01% | 5123 |
|
|
2018
Q4 | $26K | Sell |
9,200
-2,000
| -18% | -$6.58K | ﹤0.01% | 5708 |
|
|
2018
Q3 | $39K | Sell |
11,200
-3,000
| -21% | -$8.89K | ﹤0.01% | 5666 |
|
|
2018
Q2 | $45K | Buy |
14,200
+10,000
| +238% | +$31K | ﹤0.01% | 5618 |
|
|
2018
Q1 | $10K | Hold |
4,200
| – | – | ﹤0.01% | 5941 |
|
|
2017
Q4 | $24K | Buy |
4,200
+2,200
| +110% | +$11.1K | ﹤0.01% | 5743 |
|
|
2017
Q3 | $11K | Buy |
+2,000
| New | +$10.7K | ﹤0.01% | 5851 |
|
|
2017
Q2 | – | Sell |
-2,325
| Closed | -$9K | – | 6211 |
|
|
2017
Q1 | $9K | Hold |
2,325
| – | – | ﹤0.01% | 5899 |
|
|
2016
Q4 | $16K | Hold |
2,325
| – | – | ﹤0.01% | 5678 |
|
|
2016
Q3 | $18K | Buy |
2,325
+1,325
| +133% | +$10K | ﹤0.01% | 5618 |
|
|
2016
Q2 | $8K | Sell |
1,000
-517
| -34% | -$4.76K | ﹤0.01% | 5721 |
|
|
2016
Q1 | $13K | Buy |
+1,517
| New | +$13.9K | ﹤0.01% | 5612 |
|
Other funds holding AXSM
VPM
VCM
DTC
Wells Fargo's AXSM Position: Q1 2026 in Review
Wells Fargo reduced its Axsome Therapeutics (AXSM) stake by 32% in Q1 2026, selling an estimated $4.88M and leaving 61,405 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.
Wells Fargo first reported a position in AXSM in Q1 2016 and has held it in 40 quarters since. The position peaked at $16.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Wells Fargo held 61,405 shares of Axsome Therapeutics worth $10.4M as of Q1 2026.
- Wells Fargo sold 28,256 Axsome Therapeutics shares in Q1 2026, an estimated $4.88M.
- Axsome Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2004 holding.
- Wells Fargo first reported a position in Axsome Therapeutics in Q1 2016 and has held it in 40 quarters since.
- Wells Fargo's Axsome Therapeutics position peaked at $16.4M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.